Cargando…
COVID-19 vaccine associated demyelination & its association with MOG antibody
BACKGROUND: ChAdOx1-S (Covishield™/Vaxzervria, AstraZeneca) and BBV152 (Covaxin) SARS-CoV-2 vaccines are proven to be safe and effective, but rare complications have been reported. OBJECTIVE: To describe reports of central nervous system (CNS) demyelination following ChAdOx1-S and BBV152 vaccination...
Autores principales: | Netravathi, M., Dhamija, Kamakshi, Gupta, Manisha, Tamborska, Arina, Nalini, A., Holla, V.V., Nitish, L.K., Menon, Deepak, Pal, P.K., Seena, V., Yadav, Ravi, Ravindranadh, M., Faheem, Arshad, Saini, J., Mahadevan, Anita, Solomon, Tom, Singh, Bhagteshwar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8917969/ https://www.ncbi.nlm.nih.gov/pubmed/35306244 http://dx.doi.org/10.1016/j.msard.2022.103739 |
Ejemplares similares
-
Co-VAN study: COVID-19 vaccine associated neurological diseases- an experience from an apex neurosciences centre and review of the literature
por: Samim, M.M., et al.
Publicado: (2023) -
Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS
por: Kim, Sung-Min, et al.
Publicado: (2015) -
Treatment Approaches for MOG-Ab-Associated Demyelination in Children
por: Hacohen, Yael, et al.
Publicado: (2019) -
MOG antibodies in combined central and peripheral demyelination syndromes
por: Vazquez Do Campo, Rocio, et al.
Publicado: (2018) -
Epitope specificity of demyelinating MOG-specific autoantibody responses
por: Brehm, U., et al.
Publicado: (1998)